Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)

NCT05583071 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT05583071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Recruiting
Start date
August 23, 2024
Completion date
April 30, 2027
Enrollment
20 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma